MOLOGEN: Our research for you. Interim financial statements as of June 30, 2011

Transcription

1 MOLOGEN: Our research for you Interim financial statements as of June 30, 2011

2 2 Key figures MOLOGEN AG Interim financial statements as of June 30, 2011 KEY FIGURES of MOLOGEN AG for the first half of 2011 according to IFRS Balance Sheet In million 12/31/2010 Variation Cash and cash equivalents % Non-current assets % Current assets % Non-current liabilities % Current liabilities % Shareholders Equity % Equity ratio 91 % 88 % +3.4 % Income situation In million 01/01/ /01/ Variation Revenues % Personnel expenses % EBIT % Profit / loss for the period % R&D expenses % EPS in (undiluted) % Cash flow statement In million 01/01/ /01/ Variation Cash flows from operating activities % Cash flows from investing activities % Cash flows from financing activities % 6/30/2011 6/30/2010 Variation Number of employees % MOLOGEN Share 6/30/2011 6/30/2010 Variation Outstanding shares 12,459,275 10,658, % Year end price in %

3 MOLOGEN AG Interim financial statements as of June 30, 2011 Content 3 CONTENTS Letter from the Board of Directors 4 The MOLOGEN share 5 Interim management report for the 1st half of IFRS Statement of financial position as of June 30, Statement of comprehensive income for the 1st half of Statement of cash flows for the 1st half of Statement of changes in equity as of June 30, Condensed notes to the interim financial statements for the 1st half of Responsibility Statement by the Board of Directors 27 Corporate Calendar / Imprint 28

4 4 Letter from the Board of Directors MOLOGEN AG Interim financial statements as of June 30, 2011 DEAR SHAREHOLDERS, On the one hand, the first half of the year was characterized by intense work on all of our current clinical studies, and on the other hand, by the trendsetting decision to include a further cancer indication with our DNA immunomodulator MGN1703. For instance, we will now also be testing and using MGN1703 for a further big cancer indication, lung cancer. We are currently working on the application for a pivotal phase II/III study with MGN1703 for the treatment of metastatic non-small-cell lung cancer. As planned, we are thus adding another potential blockbuster in the clinical development stage to our product pipeline, especially given that lung cancer is one of the most frequently occurring cancers worldwide. We are greatly anticipating the results of the interim analysis of the colorectal cancer study, which is to start in the 2nd half of this year. The results are an important basis for licensing contracts with partners from the pharmaceutical industry. A first interim analysis of clinical phase I/II involving the cell-based gene therapy MGN1601 against renal cancer is also approaching. MGN1601 is one of the most promising medications in our product pipeline apart from MGN1703. From the very start, this renal cancer medication returned very good data regarding safety and tolerability. We are expecting further results from this study in the course of the 2nd half of the year. The very promising efficacy and tolerability data obtained in previous preclinical and clinical studies helped confirm this decision. Thanks to its universal mechanism of action, MGN1703 offers a variety of possible applications. And we are making use of this essential competitive advantage. Russia - another important market is now also included in the clinical study II/III with MGN1703 for colorectal cancer. MGN1703 is currently undergoing clinical tests at more than 20 study sites in Germany, Austria, France and Russia. When the Europe-wide patent for MGN1601 was granted in February 2011, this meant that after the USA and Russia, another important market is now patent-protected for this renal cancer medication. Apart from the development of the vaccine against hepatitis B and leishmaniasis, we are particularly hopeful as far as the interim results from our clinical studies are concerned, where we are expecting important impulses. We will be more than happy to keep you updated. Sincerely Dr. Matthias Schroff Chief Executive Officer Jörg Petraß Chief Financial Officer

5 MOLOGEN AG Interim financial statements as of June 30, 2011 The MOLOGEN share 5 The MOLOGEN share After the earthquake und the tsunami disaster in Japan and the political tensions in North Africa in the first months of the business year 2011, the stock markets stabilized again in the 2nd quarter of However, the debt problems in some countries in the Eurozone led to further uncertainty. Nonetheless, this was outweighed by the positive impact of the published economic data and profit reports. The DAX improved overall and on June 30, 2011 closed at 7,376 points, 5% above the closing rate for the 1st quarter of The MOLOGEN AG share was unable to continue the positive trend started in December After the temporary high of 9.00 in January of this year, the share was able to recover from the lower of 7.80 in March 2011, reaching a value of 8.80 in April. This was followed by a sideways movement, which apparently resulted in an increased desire to sell the share, with the price dropping to For June 30, 2011, the share was recorded at 7.95,which means 0.75 or 8.6% below the opening value for the year. The Biotech index "DAXsubsector Biotechnology" fell by approximately 7.4% in the same period. The German pharma industry index "DAXsector Pharma & Healthcare" grew by 13.2% since the start of the year. After the end of the reporting period, precisely since the beginning of August, the international financial markets are impacted by severe turbulences. All major stock market indices lost immensely and the DAX fell widely below 6,000 points. The rating agency Standard & Poor s caused extreme excitement worldwide by downgrading the credit rating of the USA. It remains to be seen whether the recession anxiety has the power to dominate the financial world for the remainder of the year or not. Performance of the MOLOGEN share in 2011 MOLOGEN AG DAXsector Pharma & Healthcare DAXsubsector Biotechnology 120% 100% 80% 60% JAN FEB MAR APR MAY JUN

6 6 The MOLOGEN share MOLOGEN AG Interim financial statements as of June 30, 2011 At the beginning of February 2011, MOLOGEN AG successfully completed a capital increase. A total of 1,245,927 of new shares were placed at an issue price of 8.00 per share. This meant that approx. 10 million were added to the company capital. Proceeds will be used to further extend the product pipeline. As part of the capital increase, numerous talks were held with investors in Germany and in adjacent foreign countries. The progress of research involving the medications MGN1703 and MGN1601 were the focus of these talks. The Annual General Meeting of MOLOGEN AG took place on June 7, with approx. 90 shareholders attending. All proposals were approved with a clear majority. Share data Ticker symbol ISIN Share type Market segment DAXsector DAXsubsector Exchanges Designated Sponsor MGN DE Bearer shares without par-value Regulated market (Prime Standard) Pharma & Healthcare Biotechnology XETRA, Frankfurt, Berlin, Düsseldorf, Hamburg, Munich, Stuttgart Close Brothers Seydler Bank AG, equinet Bank AG Share key figures XETRA 1st half of st half of 2010 Number of issued shares on June 30 12,459,275 10,658,348 Market capitalization on June 30 ( million) First trading day ( ) Last trading day ( ) High ( ) Low ( ) Average daily traded volume (shares) 11,209 9,653 Shareholder structure Baden-Würtemmbergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte Deutscher Ring Sachversicherungs AG, Hamburg 8 BUCHRI GmbH, Berlin Deutscher Ring Lebensversicherungs AG, Hamburg 9 Deutscher Ring Krankenversicherungsverein a.g., Hamburg Salvator Vermögensverwaltungs GmbH, Munich 10 Free float

7 MOLOGEN AG Interim financial statements as of June 30, 2011 Interim management report 7 INTERIM MANAGEMENT REPORT for the period from January 1 to June 30, 2011 Result of -3.2 million (01/01-: -3.0 million). EBIT of -3.2 million (01/01-: -3.0 million). Average monthly net use of cash and cash equivalents of 0.4 million (2010: 0.5 million). Cash and cash equivalents of 11.4 million (12/31/2010: 4.7 million). Economic Environment General Economic Development After the record-breaking year 2010, which showed the biggest growth of Germany's gross domestic product (GDP) of 3.6% since the Reunification, the outlook for 2011 is also favorable. In its spring forecast published in April, the Federal Government assumes a stable GDP growth of 2.6%, thereby increasing the annual forecast published in January 2011 by 0.3 percentage points. The International Monetary Fund (IMF) in its most recent estimate dated June 2011 even expects an increase of 3.2%. Economic development Favorable forecast for 2011 Increased risk of inflation Uncertainty due to debt crisis The global recovery also continues but with strong regional differences, showing a significant slow-down towards the end of the half year. The economies of developing and emerging countries continue to be the drivers of growth, with Asia standing out particularly with a forecast GDP growth of 8.4%. According to its most recent forecast for 2011, the IMF expects a growth of 6.6% in the emerging markets and of only 2.2% in the industrial nations. In the US, for instance, a slightly slower GDP increase of 2.5% is expected (previously 2.8%). All in all, the IMF assumes a growth of the global economy of 4.3%. The outlook for the Japanese economy suffered from the severe earthquake in March of this year and from its consequences. The IMF reduced its forecast by 2.1 percentage points and expects a reduction of GDP by 0.7%. The positive developments of the past year and the first half of 2011 as well as the favorable economic forecasts also affect the employment market, albeit to a varying degree. In June, the unemployment rate in Germany was at 6.9%. The Federal Government expects the unemployment rate to remain on a similar level at the end of the year, with those employed making up roughly 40.9 million people. The IMF also expects a positive development in the US, anticipating a reduction in the unemployment rate from 9.6% to 8.5%. However, the unemployment rate recently went up again and was at 9.2% in June. In the Eurozone, only a small improvement of the unemployment rate of 0.1 percentage points to 9.9% is expected overall.

8 8 Interim management report MOLOGEN AG Interim financial statements as of June 30, 2011 These favorable forecasts are accompanied by an increase in commodity and consumer prices. In its most recent estimates, the IMF also expects strong increases, e.g. of more than 34% for oil and of 6.9% for consumer prices in developing and emerging markets. A stronger increase in consumer prices than previously of 2.6% is expected for the industrial nations. Uncertainty is also intensified by the return of worries about state debt. Apart from Greece, the financial difficulties of the US as well as Italy and other Southern European countries further negatively affect forecasts. In addition, there were the geopolitical instabilities in the Middle East and North Africa. In the US, interest will remain on a very low level. This year, the American Federal Bank still kept its base rate unchanged at a level between 0% and 0.25%. The European Central Bank, however, increased its base rate in April for the first time in almost three years from 1% to 1.25% and by a further 0.25 percentage points to now 1.50% in July in order to counteract increasing inflation in the Eurozone. Challenges of the pharma industry Reduced growth until 2015 Extension of the market share of generic drugs Patent expiries for 11 of the top 20 brand products Oncology remains the leading therapy class Development of pharma and biotechnology industry According to the forecast by the market research institute IMS Health in May 2011, in the next five years, the global pharma market will grow more slowly than between 2005 and The institute expects an increase in expenditure for medication from US$ 856 billion to nearly US$ 1.1 trillion. This corresponds to an average annual growth rate of approx. 5%, whereas in the last five years, the annual growth rate averaged at 6.2%. Experts expect growth to show strong regional variations. The market share of emerging countries, led by China, will increase by approx. 10% to 28% in the next five years, whereas the market share of the USA and the five biggest European markets of 53% in the past will fall to 44% by The significance of generic drugs will further increase. They will significantly impact growth in the coming years. Revenues from brand products in the industrial nations will stagnate in the next five years. The market entry of new patent-protected drugs is offset by the expiry of patents relating to 11 of the 20 currently strongest brand products in terms of revenue. According to the IMS Health forecasts, generic drugs will reach a global market share of 39% in 2015, corresponding to an increase of approx. 12 percentage points compared to the previous year.

9 MOLOGEN AG Interim financial statements as of June 30, 2011 Interim management report 9 In line with the slower growth of the overall pharma market, the revenues in most therapy areas will also increase much more slowly than in the past five years. Oncology will remain the leading therapy class in terms of revenue with an annual growth rate of approx. 5-8 % and an estimated market volume of US$ billion in However, the industry still faces big challenges. The extension of market shares for generic medication, budgeting for health expenditure as well as regulatory and technological risks are key topics. This will lead to an increase in the interdependence of pharma and biotechnology companies. The latest most prominent example of this was the takeover of the US biotechnology company Genzyme by the French pharma company Sanofi-Aventis, which was agreed in April Against this background, the stock market environment for innovative biotechnology companies like MOLOGEN AG (short: MOLOGEN) can continue to be regarded as favorable in the long term. It is expected that the progress in the clinical development programs of MOLOGEN will also have a positive effect on the perception of the company on the capital market. Business trend Research and Development (R&D) The objective of MOLOGEN is to develop highly innovative medication for the treatment of cancer and severe infectious diseases based on its own platform technologies. In the first half of the business year 2011, important progress could again be made in the company's research and development strategy. The implementation of current clinical studies was at the center of R&D activities in the reporting period.

10 10 Interim management report MOLOGEN AG Interim financial statements as of June 30, 2011 The product pipeline is made up of the following: Product Research Pre-Clinic Phase I Phase II Phase III Approval Oncology MGN1703-CRC colorectal cancer MGN1703-NSCLC non-small cell lung cancer other malignant tumors MGN1601-RCC renal cell carcinoma Infectious Diseases MGN1331 leishmaniasis MGN1333 hepatitis B Cancer medication MGN1703 MGN1703 Very good tolerability so far Interim analysis of the colorectal cancer study is to start in the second half of 2011 Study on lung cancer under preparation Colorectal cancer study In the clinical study of phase II/III, the cancer medication MGN1703 for the treatment of metastatic colorectal cancer has so far shown very good tolerability. This is remarkable in that the highest dose of the previous clinical phase lb study was used for the current study. The dose used was significantly higher than the dosage previously used by competitors in comparative clinical studies. For MGN1703, this was made possible by the dslim DNA molecule developed by MOLOGEN, which keeps side effects low due to its unique structure. The randomized, placebo-controlled, double-blinded, multicenter clinical study of phase II/III ("IMPACT" study) is designed as a pivotal, confirmatory study to confirm the efficacy of MGN1703 when treating metastatic colorectal cancer with statistical significance. As part of the study, MGN1703 is administered to patients subcutaneously (injection under the skin) twice a week. Treatment continues until a renewed progression of the cancer disease is identified. The objective is to prevent a relapse or the renewed progression of the disease for much longer than is currently possible with existing, already approved medications. As a result, the primary goal of the study is the progression-free survival and overall survival of the patients. Additional study goals include the determination of immunological pharmacodynamic parameters. First statements regarding the achievement of study targets will presumably be available after the interim analysis, which is to start in the second half of The clinical study is currently carried out in more than 20 centers in Germany, Austria, France and Russia.

11 MOLOGEN AG Interim financial statements as of June 30, 2011 Interim management report 11 Lung cancer study MOLOGEN will investigate the cancer medication MGN1703 also for the treatment of lung cancer. For this purpose, the application for a pivotal clinical study of phase II/III is currently being prepared. As part of this clinical study, the efficacy of MGN1703 for the treatment of metastatic non-small-cell lung cancer (NSCLC) is to be investigated. The aim of the study is to prevent the disease from progressing for a longer period than possible using current therapy forms. As part of the study, the so-called progression-free survival of approx. 200 patients is to be investigated. This new clinical lung cancer study will, like the colorectal cancer study, start in the pivotal phase II/III. This means that the international study will be placebo-controlled, randomized and blinded. The universal mechanism of action of MGN1703 is based on a broad activation of the immune system in a way required to successfully combat cancer. This allows MOLO- GEN to use MGN1703 for very different cancer indications. Cell-based gene therapy for renal cancer (MGN1601) The clinical study of phase I/II of the renal cancer medication MGN1601 also showed very good safety and tolerability levels at the start. As part of the study commenced in December 2010, patients may be both admitted and treated at the same time since January 2011, which for the first patients had to be performed successively for safety reasons with a subsequent observation period. Treatment with MGN1601 is tolerated excellently and has currently not shown any considerable side effects. As a result, the medication so far fully meets expectations. MGN1601 Very good tolerability so far First results of the renal cancer study in the second half of 2011 The clinical phase I/II study ("ASET" study) is to investigate the efficacy of MGN1601. In this clinical study, patients are to be included who suffer from advanced renal cancer and have not responded to standard therapy. Apart from the safety and tolerability data of the medication, efficacy data is also determined, containing the clinical, immunological and radiological parameters of the patients. The clinical study is carried out in three centers in Berlin, Hanover and Bonn. Vaccines Additional R&D activities in the area of leishmaniasis with the vaccine candidates MGN1331 and hepatitis B with the vaccine candidate MGN1333 continued as planned in the reporting period.

12 12 Interim management report MOLOGEN AG Interim financial statements as of June 30, 2011 R&D expenses (IFRS) in million R&D expenses Reaching milestones in the R&D area is an important basis for the further positive development of the company. In the first six months of the business year 2011, therefore, measures and investments of 2.6 million (comparison period) 2.1 million) were recognized as expenditure in relation to these milestones. 06/30/ /30/ 2011 Financial performance and financial position Results of operations In the first half of 2011, as in the first six months of the previous year, MOLOGEN's revenues of 67 thousand were low as expected (comparison period: 36 thousand). Since more subsidies were received in this compared to the reporting period, other operating income of 350 thousand was significantly higher than in the previous year ( 13 thousand). Profit/loss for the period (IFRS) in million 06/30/ /30/ 2011 The loss in the reporting period was 3,184 thousand which is higher than the loss in the comparison period ( 2,959 thousand). The higher revenues, higher other operating income, lower depreciations ( 144 thousand, comparison period: 227 thousand) and higher financing income ( 57 thousand; comparison period approx. 18 thousand) were set off by higher material expenses, higher personnel expenses and higher other operating expenses Expenditure for current clinical studies resulted in higher material expenses ( 731 thousand, comparison period: 637 thousand). Higher research expenditure and higher expenditure for consultancy services in the field of Marketing and Investor Relations led to an increase in other operating expenses ( 1,220 thousand; comparison: 979 thousand). Personnel expenses ( 1,562 thousand; comparison period: 1,183 thousand) went up as more staff were employed and due to higher expenses in the context of granted share options. The number of employees in the research and development area increased significantly compared to the prior year balance sheet date. On June 30, 2011, a total of 49 employees (including management) were working for MOLOGEN (6/30/2010: 44 employees including management). Cash and cash equivalents (IFRS) inmillion /31/ /30/ 2011 Asset and financial position Assets contain a large proportion of cash and cash equivalents, which amounted to 11,441 thousand on the reporting date (12/31/2010: 4,722 thousand). The increase is due to the capital increase in February 2011 and to the related issue of 1,245,927 new shares. As part of a rights offer, shareholders were given the right to buy new shares. The subscription ratio was set at 9:1, i.e. for every nine existing MO- LOGEN shares, one new share could be bought at the price of After the end of the subscription period, unpurchased new shares were sold to interested parties as part of an international private placement at a price of In total, existing share-

13 MOLOGEN AG Interim financial statements as of June 30, 2011 Interim management report 13 holders exercised more than 40% of subscription rights. The shares offered as part of the private placement were significantly oversubscribed. Cash flows from the capital increase were 9,967 thousand gross and served to strengthen the equity capital basis. It is used to finance further company growth, to extend the product pipeline and to finance the necessary operations. The capital increase was registered in the trade register on February 4, The new shares are entitled to profits from January 1, Liabilities are characterized by shareholders equity of 12,691 thousand (12/31/2010: 6,202 thousand), which was strengthened by the capital measure. Due to the measure, the authorized capital of MOLOGEN increased from 11,213, by approx. 11% to 12,459, The equity ratio increased to 91% and is now above the value at the end of the year 2010 (12/31/2010: 88%). Opportunity and risk report The extraordinary revenue opportunities of MOLOGEN are offset by the risks common to the industry. These include technological, financial, regulatory, patent and sales risks. The opportunities and risks resulting from the business model and business activities of MOLOGEN are described in detail in the Annual Report 2010 (p. 40 ff.). Unless stated otherwise, these continue to apply. Equity ratio (IFRS) in % 88 12/31/ /30/ 2011 Information on relevant events after the end of the reporting period There were no significant events after the balance sheet date June 30, Forecast In the next two years, MOLOGEN will intensely drive forward the further development of the product pipeline. For the current business year 2011, the company assumes the expectations set out in the Annual Report In this context, the continuing clinical studies involving the cancer medications MGN1703 and MGN1601, the implementation of the interim analysis of the study involving MGN1703 and the application for a further clinical study with MGN1703 for the indication lung cancer must be stressed especially. Additionally, MOLOGEN aims at concluding a license agreement with a partner in the pharmaceutical industry regarding the cancer medication MGN1703.

14 14 Interim management report MOLOGEN AG Interim financial statements as of June 30, 2011 Furthermore, the company strategy is designed to achieve medium- and long-term high returns through research and the further development of the innovative product pipeline. In order to achieve this objective, measures and investments to be recognized as expenditure - impacting on the short-term positive development of results - will also be necessary in 2011 and Against this background, above all in 2011, MOLOGEN again expects a negative annual result and increased losses. Progress in the clinical development programs already made this year are to further increase the value of the product pipeline together with the objectives for As a result, MOLOGEN takes an optimistic view of the rest of the year. Berlin, August 11, 2011 MOLOGEN AG Board of Directors Dr. Matthias Schroff Chief Executive Officer Jörg Petraß Chief Financial Officer

15 MOLOGEN AG Interim financial statements as of June 30, 2011 IFRS Statement of financial position 15 IFRS Statement of financial position as of June 30, 2011 EUR '000 6/30/ /31/2010 ASSETS Non-current assets 1,411 1,548 Tangible assets Intangible assets 1,255 1,371 Investments 0 0 Other non-current assets 4 4 Current assets 12,471 5,536 Cash and cash equivalents 11,441 4,722 Inventories Other current assets Income tax receivables Total 13,882 7,084 LIABILITIES Non-current liabilities Deferred revenues Current liabilities 1, Trade payables Other current liabilities and accruals Liabilities to banks 16 6 Shareholders Equity 12,691 6,202 Paid-in capital 12,459 11,213 Capital reserves 44,231 35,804 Accumulated losses -43,999-40,815 Total 13,882 7,084

16 16 IFRS Statement of comprehensive income MOLOGEN AG Interim financial statements as of June 30, 2011 IFRS STATEMENT OF COMPREHENSIVE INCOME for the period from January 1 to June 30, 2011 EUR '000 01/01/ /01/ /01/ /01/ Revenues Other operating income Cost of materials Personnel costs -1, , Depreciation and amortization expenses Other operating expenses -1, Operating result -3,240-1,718-2,977-1,402 Finance costs Finance income Earnings before taxes -3,184-1,684-2,959-1,397 Tax result Profit / loss for the period/ Comprehensive income -3,184-1,684-2,959-1,397 Net loss carried forward -40,815-42,315-35,164-36,726 Accumulated losses -43,999-43,999-38,123-38,123 Basic earnings per share (in ) Diluted earnings per share (in )

17 MOLOGEN AG Interim financial statements as of June 30, 2011 Statement of cash flows 17 IFRS STATEMENT OF CASH FLOWS for the period from January 1 to June 30, 2011 EUR '000 01/01/ /01/ Cash flows from operating activities Earnings before taxes -3,184-2,959 Depreciation and amortization of fixed assets Loss on disposal of fixed assets 1 0 Decrease in provisions 0 0 Other non-cash expenses and income Change in trade receivables, inventories and other assets Change in debts and other liabilities Net cash used in operating activities -2,589-2,962 Cash flows from investing activities Purchase of property, plant and equipment, classified as investing activities Purchase of intangible assets, classified as investing activities 0-2 Net cash used in investing activities Cash flows from financing activities Cash receipts from issue of capital 9,316 3,216 Net cash used in financing activities 9,316 3,216 Foreign currency effect on cash and cash equivalents 0 0 Total changes in liquidity (Cash flow) 6, Cash and cash equivalents at the beginning of the period 4,722 6,174 Cash and cash equivalents at the end of the period 11,441 6,406

18 18 Statement of changes in equity MOLOGEN AG Interim financial statements as of June 30, 2011 IFRS STATEMENT OF CHANGES IN EQUITY as of June 30, 2011 EUR '000 except share values Paid-in capital Number of ordinary - shares Share capital Deposits made to effect the agreed capital increase Capital reserves Accumulated losses Shareholders Equity As of Dec. 31, ,143,348 10,143 3,574 28,798-35,164 7,351 Capital increase in exchange for cash contributions 512, ,691 3,199 Share options exercised 3, Value of services rendered by employees (according to IFRS 2) Profit / loss for the period -2,959-2,959 As of June 30, ,658,348 10,658 3,570 31,604-38,123 7,709 As of Dec. 31, ,213,348 11, ,804-40,815 6,202 Capital increase in exchange for cash contributions 1,245,927 1, ,070 9,316 Value of services rendered by employees (according to IFRS 2) Profit / loss for the period -3,184-3,184 As of June 30, ,459,275 12, ,231-43,999 12,691

19 MOLOGEN AG Interim financial statements as of June 30, 2011 Notes 19 CONDENSED NOTES for the period of January 1 to June 30, 2011 A. General information about the company MOLOGEN AG (short: MOLOGEN) is a stock corporation headquartered in Berlin (Fabeckstraße 30, Berlin, Germany). It was founded on January 14, 1998 and is registered at the Berlin-Charlottenburg District Court under Trade Register entry HRB B. The shares of the company are listed on the regulated market (Prime Standard) at the Frankfurt Stock Exchange under ISIN DE The objective of the company is the research and development and the marketing of products in the field of molecular medicine. This mostly encompasses bio-molecular vaccines, application-oriented clinical research in the field of bio-molecular tumor therapy and somatic gene therapy. The main focus of research is on the MIDGE and dsllm technologies patented by MOLOGEN. These enable the use of DNA as medication against previously untreatable diseases or diseases for which treatment is insufficient. B. General information about the financial statements The present unaudited, abbreviated interim statements of MOLOGEN were compiled according to the IFRS as applied in the EU for the reporting date June 30, They were compiled in accordance with IAS 34 (Interim financial reporting) and are to be read in conjunction with the audited financial statements of MO- LOGEN as of December 31, 2010, which were compiled according to IFRS as applied in the EU. The accounting and valuation methods were applied in the same way as for December 31, All new and amended accounting standards to be applied in the reporting period for the first time do not significantly impact on MOLOGEN's interim statements. The reporting period in the sense of these short interim statements is the period between January 1, 2011 and June 30, The comparative period in the sense of these condensed interim financial statements for the statement of comprehensive income is the period between January 1, 2010 and June 30, 2010 and the period between April 1, 2010 and June 30, The functional currency and reporting currency in the financial statements is the Euro ( ). In order to facilitate understanding, the figures were rounded and shown in thousand Euro (T ) unless stated otherwise.

20 20 Notes MOLOGEN AG Interim financial statements as of June 30, 2011 C. Selected notes relating to the statement of financial position as of June 30, 2011 Assets Tangible assets / Intangible assets In the reporting period, tangible assets to the value of 8 thousand were acquired (12/31/2010: 47 thousand). No intangible assets were acquired (12/31/2010: 2 thousand). There were no significant disposals. There were no indications demanding extraordinary value adjustments. Cash and cash equivalents Cash and cash equivalents comprise cash and bank balances. Bank balances are held at variable interest rates. Short-term investments are for different periods up to six months, which are determined depending on the company's demand for cash flow. They are invested at fixed interest rates. The value of cash and cash equivalents and short-term investments at the reporting date was 11,441 thousand (12/31/2010: 4,722 thousand). This is based on the nominal value of the Euro holdings and the recognition of a foreign currency account converted using the exchange rate valid on. Other current assets and deferred income tax entitlements EUR '000 6/30/ /31/2010 Deferred revenues Reimbursements from VAT Income tax entitlements Claims against tax authorities for investment subsidy 4 4 Other receivables In the reporting period and in the business year 2010, no value adjustments were recorded for other assets. Liabilities Non-current liabilities The amount recognized as accrual items of 75 thousand (12/31/2010: 80 thousand) relates to public grants for assets ( 12 thousand; 12/31/2010: 14 thousand) and deferred revenue ( 63 thousand; 31/12/2010: 66 thousand).

21 MOLOGEN AG Interim financial statements as of June 30, 2011 Notes 21 Current liabilities EUR '000 12/31/2010 Trade payables Deferred revenues Liabilities from income and church tax Deposits received for orders Liabilities to banks 16 6 Other liabilities , Accrual items of 208 thousand (12/31/2010: 91 thousand) mainly consist of grants from the 7th Framework Programme of the European Union of 201 thousand (12/31/2010: 84 thousand). Shareholders equity The composition of equity and the development of equity components are shown in the Statement of Changes in Equity. Paid-in capital The paid-in capital of MOLOGEN of 12,459, is subscribed capital, divided into 12,459,275 no-par bearer shares each with a notional share of 1.00 in the share capital. In the reporting period, MOLOGEN carried out the following measures affecting capital: On January 13, 2011, the MOLOGEN Board of Directors, with approval of the Supervisory Board, resolved to use authorized capital according to Section 4 (3) of the Articles of Association, resulting in a capital increase with a rights issue for shareholders. The Board of Directors set the price for the 1,245,927 new shares offered and placed as part of the rights offer at 8.00 per share with the Supervisory Board's approval. The gross issue proceeds were 10 million. The capital increase was entered in the trade register for the company on February 4, At the point, paid-in capital increased by 1,245,927 from 11,213,348 to 12,459,275. Authorized capital The Annual General Meeting on June 7, 2011 authorized the Board of Directors to annul the existing authorized capital, which, after partial use in the context of the capital increase registered in the trade register on February 4, 2011 was still at 4,081, and to create a new authorized capital. Until June 6, 2016, the company's share capital may be increased with the Supervisory Board's approval by issuing new no-par bearer shares in return for contributions in kind and/or cash payments, either once or several times, however only up to a maximum of 6,229,

22 22 Notes MOLOGEN AG Interim financial statements as of June 30, 2011 Conditional capital Details regarding the conditional capitals can be found in the Annual Report The following changes occurred in the reporting period: By resolution in the Annual General Meeting on June 7, 2011, conditional capital 2007, which was at 179,234.00, divided into 179,234 no-par bearer shares, was annulled. By resolution in the Annual General Meeting on June 7, 2011, conditional capital 2011, which was at 238,393.00, divided into 238,393 no-par bearer shares, was created. The conditional capital 2011 is used to grant convertible bonds and/or subscription rights without issuing debt securities to the members of the Board and the employees of the company. On June 10, 2011, the resolutions by the Annual General Meeting on June 7, 2011 were entered in the trade register. At the end of the reporting period on Thursday, June 30, 2011, the company had the following authorized and conditional capitals: EUR '000 12/31/2010 Variation Authorized capital 6,229,637 5,327, ,963 Conditional capital , ,234 Conditional capital ,770,739 3,770,739 0 Conditional capital , ,149 0 Conditional capital , ,151 0 Conditional capital , ,393 Capital reserves In the reporting period, costs of 651 thousand were incurred due to exercising share options and carrying out capital measures (01/01 - : 386 thousand). These costs were taken into account in the capital reserves according to IAS The application of IFRS 2 (Share-based payment) resulted in additions to the capital reserve in the reporting period of 357 thousand (01/01-03/31/2010: 101 thousand). EUR '000 12/31/2010 Capital reserves 43,857 35,136 Employee compensation in equity instruments 3,392 3,035 Costs of equity procurement -3,018-2,367 44,231 35,804

23 MOLOGEN AG Interim financial statements as of June 30, 2011 Notes 23 D. Selected notes to the statement of comprehensive income Other operating income EUR '000 01/01/ /01/ /01/ /01/ Funding Others Personnel expenses EUR '000 01/01/ /01/ /01/ /01/ Wages and salaries 1, Social insurance contributions Stock options granted (according to IFRS 2) , , The increase in personnel expenses compared to the prior period (: 1,562 thousand; 6/30/2010: 1,183 thousand) was due to the hiring of new staff and to higher expenses in the context of granted share options. Other operating expenses EUR '000 01/01/ /01/ /01/ /01/ Other operating expenses 1, The increase in other operating expenses was due to increased research expenditure and to increased expenditure for consultancy in the field of Marketing and Investor Relations.

24 24 Notes MOLOGEN AG Interim financial statements as of June 30, 2011 Research and Development (R&D) The resources available to the company were largely used directly for research projects. There were no development costs in the reporting period or the comparison period. EUR '000 01/01/ /01/ /01/ /01/ R&D expenditure 2,558 1,472 2, Earnings per share (EPS) Undiluted earnings per share are calculated by dividing the earnings attributable to the owners of the ordinary shares of the company by the weighted average number of ordinary shares in circulation during the financial year. Diluted earnings per share are calculated by dividing the earnings attributable to the owners of the ordinary shares of the company by the weighted average number of ordinary shares in circulation during the financial year plus the weighted average number of ordinary shares arising from the conversion of all potential ordinary shares with the dilution effect into ordinary shares. 01/01/ /01/ /01/ /01/ Earnings before taxes (1) EUR '000-3,184-1,684-2,959-1,397 Weighted average number of ordinary shares for calculating the undiluted earnings per share in thousands 12,218 12,459 10,599 10,655 Dilution effect from the issue of stock options in thousands Weighted average number of ordinary shares including the dilution effect in thousands 12,218 12,459 10,599 10,655 Basic EPS in Diluted EPS in (2) (2) (2) (2) (1) (2) Earnings attributable to the owners of ordinary shares of the company. Share options granted in the previous years did not result in any dilution effects in the sense of IAS ff.

25 MOLOGEN AG Interim financial statements as of June 30, 2011 Notes 25 E. Notes on the statement of cash flows The cash flow statement shows how the cash and cash equivalents of MOLOGEN have changed due to additions and disposals of cash in the reporting period. According to IAS 7, there is a distinction between operating activities, investing activities and financing activities. The cash flow from operations contains interest-affecting income of 22 thousand (01/01 : 5 thousand). No interest was paid in the reporting period or in the comparison period. F. Notes on the employee participation programs The company has set up several share-based employee participation programs. Details regarding sharebased employee participation programs can be found in the Annual Report 2010 (Section F of the Notes to the IFRS Annual Financial Statements). No new stock option program was started in the reporting period. As part of the stock option program 2010, not yet allocated stock options were granted to employees of the company. The following table shows the number and the weighted average exercise prices (WAEP) as well as the development of the stock options during the reporting period. WAEP per option in Number of options (units) As of January 01, ,892 Granted (1) ,657 Forfeited 0 Exercised 0 Expired 0 As of June 30, ,549 Can be exercised by 30 June 2011 (2) 0 (1) (2) The weighted average fair value of options granted during the reporting period was The only factor taken into account here is whether the waiting period of the options has already expired. All other contractual obligations, such as the attainment of the performance target, were disregarded. The weighted average remaining contractual duration for the options outstanding as of June 30, 2011 is 5.51 years. The exercise prices for options outstanding at the end of the reporting period range between 6.95 and 8.93.

26 26 Notes MOLOGEN AG Interim financial statements as of June 30, 2011 G. Notes on the type and management of financial risks Details relating to the risks resulting from financial instruments and to financial risk management can be found in Section H of the Notes to the Annual Report No additional information is required in relation to the risks described there. H. Notes on affiliated persons Directors Dealings In the reporting period, directors informed the company of the following securities dealings subject to reporting according to Section 15a of the Securities Trading Act (WpHG). Name, Position Date Transaction Number of shares Price in Trading volume in Market Hella Schlichting (2) 03/30/2011 Sales 1, , XETRA Dr. Matthias Schroff 03/31/2011 Purchase , XETRA Dr. Matthias Schroff 03/31/2011 Purchase , XETRA Jörg Petraß (1) 04/11/2011 Purchase , XETRA Jörg Petraß (1) 04/11/2011 Purchase 1, , XETRA Hella Schlichting (2) 06/10/2011 Sales 2, , XETRA Frankfurt (1) (2) Member of the Board of Directors Natural person in close relationship to a member of the Supervisory Board I. Other information Approval of the financial statements The financial statements were approved by the Board of Directors on August 11, 2011 and released for publication. Berlin, August 11, 2011 MOLOGEN AG Board of Directors Dr. Matthias Schroff Chief Executive Officer Jörg Petraß Chief Financial Officer

27 MOLOGEN AG Interim financial statements as of June 30, 2011 Responsibility statement 27 RESPONSIBILITY STATEMENT BY THE BOARD OF DIRECTORS To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the company, and the interim management report includes a fair review of the development and performance of the business and the position of the company, together with a description of the principal opportunities and risks associated with the expected development of the company for the remaining months of the financial year. Berlin, August 11; 2011 MOLOGEN AG Board of Directors Dr. Matthias Schroff Chief Executive Officer Jörg Petraß Chief Financial Officer

28 28 Corporate Calendar / Imprint MOLOGEN AG Interim report as at 30 June 2011 CORPORATE CALENDAR 2011 March 30, 2011 Publication of financial statements 2010 May12, 2011 Quarterly report as of March 31, 2011 June 7, 2011 Annual General Meeting 2011 August 12, 2011 Half-year report as of June 30, 2011 August 29, th DVFA SCC Small Cap Conference November 14, 2011 Quarterly report as of September 30, 2011 November 22-24, 2011 German Equity Capital Forum (Deutsches Eigenkapitalforum), Fall 2011 NOTE This information contains statements relating to the future, which are based on assumptions and estimates made by the management of MOLOGEN AG. By using words such as expect, intend, plan, predict, assume, believe, estimate etc., we are marking such statements as relating to the future. Such statements should not be taken as guarantees that these expectations will turn out to be correct. The future development and results submitted by MOLOGEN AG depend on a number of risks and uncertainties and can hence vary significantly from the statements about the future. Some of these factors are outside the realm of influence of MOLOGEN AG and cannot be forecasted accurately, e.g. the future economic environment and the behavior of competitors and other market participants. An update of statements relating to the future has neither been planned nor does MOLOGEN accept a separate obligation regarding this. IMPRINT Publisher: MOLOGEN AG Fabeckstr. 30 D Berlin Tel.: Fax: info@mologen.com